Basic Super P Force Information

• INN (International Nonproprietary Name): Sildenafil (PDE5 inhibitor); Dapoxetine (Selective Serotonin Reuptake Inhibitor, SSRI).
• Brand Names Available In Canada (English): not specified.
• ATC Code: Sildenafil — G04BE03 (Drugs used in erectile dysfunction; phosphodiesterase type-5 inhibitors). Dapoxetine — not officially assigned; often considered under N06BX21 in some regulatory databases. Combination products may not have a single ATC code — refer to individual substances.
• Forms & Dosages: Tablet, 100mg/60mg (Sildenafil 100mg + Dapoxetine 60mg), oral, typically sold in blister packs of 4, 8, 12, or 24 tablets.
• Manufacturers In Canada (English): not specified.
• Registration Status In Canada (English): not specified.
• OTC / Rx Classification: Prescription-only (Rx) in regulated countries.

Latest Research Highlights (Canadian & International, 2022–2025)

Patients ask whether one tablet can safely treat both erectile dysfunction and premature ejaculation.

Recent evidence continues to separate the established efficacy of individual actives — sildenafil for ED and dapoxetine for PE — from the limited data supporting fixed-dose combinations such as Super P‑Force.

Canadian-specific trials are sparse and searches of Health Canada registries up to 2025 show few or no registered trials on the 100mg/60mg sildenafil‑dapoxetine fixed combination.

Internationally, dapoxetine randomised controlled trials and meta-analyses done before the 2020s show benefit for premature ejaculation when used as a PRN agent.

Sildenafil has robust long-term clinical trial and safety data demonstrating effectiveness for erectile dysfunction in multiple populations.

Post‑2022 literature flags safety signals when combining PDE5 inhibitors with serotonergic agents, including dizziness, syncope and rare reports compatible with serotonin syndrome, which encourages clinical caution.

Regulatory activity in the US and EU emphasises that combination formulations often remain unapproved without dedicated combination trials and labelled safety data.

Patient‑centred takeaway: evidence supports separate, supervised prescribing of sildenafil and dapoxetine rather than relying on imported fixed combos that lack Health Canada approval and high‑quality Canadian RCT evidence.

Clinical Effectiveness In Canada (Health Canada Context & Dins)

Many Canadians want to know whether the combo is recognised by Health Canada and covered locally.

Health Canada approves sildenafil as an ED treatment under multiple DIN‑bearing products, including brand and generic formulations supplied by established manufacturers.

Dapoxetine is not commonly marketed in Canada and product availability is limited, often requiring special import routes or compassionate access.

The Super P‑Force fixed combination (sildenafil 100mg + dapoxetine 60mg) has no known Health Canada approval or assigned DIN as a combination product.

Clinicians in Canada therefore rely on individual active approvals when treating ED or PE rather than prescribing an unapproved combined tablet.

• Sources To Verify Approval: Health Canada Drug Product Database; provincial formularies such as ODB, BC PharmaCare and RAMQ.

Data highlight: there is no DIN for the combination product; individual DINs exist for sildenafil generics.

Practical implication: provincial drug plans typically reimburse listed DINs, and expect no coverage for unapproved imported combination tablets.

Indications And Expanded Uses (Approved Vs Off‑Label In Canadian Practice)

People often ask whether Super P‑Force is intended for both ED and PE in Canada.

Approved

Sildenafil — erectile dysfunction.

Off‑Label/limited Access

Dapoxetine — premature ejaculation; generally not widely marketed in Canada.

Combination

Super P‑Force — unapproved in Canada.

Super P‑Force is presented internationally for concurrent ED and PE, but in Canada its use would be off‑label and typically discouraged without specialist oversight.

Clinicians should document diagnostic criteria using validated ED and PE scales and assess cardiovascular risk before prescribing sildenafil or dapoxetine.

Patient counselling should include a discussion about risks of combining PDE5 inhibitors with serotonergic agents and the lack of Canadian approval for combination tablets.

Canadian prescribers may encounter patients requesting imported combos via online pharmacies and should counsel about variable potency, counterfeit risk and lack of local oversight.

Composition And Brand Landscape (Actives, Manufacturers, Generics)

One frequent patient worry is who makes these tablets and whether the packaging is reliable.

Super P‑Force combines sildenafil 100mg and dapoxetine 60mg in an oral tablet format sold in blister packs by international manufacturers.

• Key Manufacturing / Import Risks: variable quality, counterfeit risk, unknown storage controls during shipping.

Common manufacturers listed in international sources include Indian companies such as Sunrise Remedies and Centurion Laboratories for export markets.

Health Canada classifies such combination imports as unlicensed and products without a DIN are not covered by provincial plans or major pharmacy chains in Canada.

Contraindications And Special Precautions (Canadian High‑Risk Groups)

Patients often ask who should never take this combination.

Absolute contraindications include hypersensitivity to sildenafil or dapoxetine, concurrent nitrate use, recent stroke or unstable cardiac disease, history of mania or bipolar disorder, and severe liver impairment.

Relative contraindications include moderate liver/kidney dysfunction, anatomical penile deformities, bleeding disorders, epilepsy and significant cardiovascular disease where specialist review is advised.

• High‑Risk Canadian Groups: elderly patients on nitrates, people with ischaemic heart disease, residents of remote communities with limited emergency access, and those with hepatic or renal impairment.

Data highlight: serotonergic interactions with dapoxetine raise the risk of serotonin syndrome when combined with SSRIs or MAO inhibitors.

Clinicians should perform complete medication reconciliation and document informed consent if considering off‑label imported products for patients in high‑risk groups.

Dosage Guidelines (Canadian Dosing Schedules & Adjustments)

People want clear instructions for safe dosing and what to do if they have liver or kidney disease.

The standard international regimen for Super P‑Force is one tablet taken 1–3 hours before sexual activity with a maximum of one tablet per 24 hours.

In Canada, clinicians typically prescribe sildenafil per licensed dosing between 25–100mg adjusted for comorbidities and consider dapoxetine dosing if it is accessed through appropriate channels.

PRN Use

As needed, 1–3 hours before activity; not for chronic daily therapy.

Dose Adjustments

Lower sildenafil dose for significant liver or kidney impairment and when used with potent CYP3A4 inhibitors; avoid or reduce dapoxetine in hepatic impairment and use caution in the elderly.

When to lower dose: moderate renal dysfunction, potent CYP3A4 inhibitors and age over 65 with comorbidity.

Provincial formularies may require prior authorisation for non‑standard dosing or off‑label reimbursement requests.

Interactions Overview (Foods, Drugs, Canadian Lifestyle Factors)

Many callers ask whether alcohol or their antidepressant will interact with these tablets.

Key dangerous interactions include nitrates, which may cause severe hypotension when combined with sildenafil.

Potent CYP3A4 inhibitors such as certain antifungals and some HIV protease inhibitors can increase sildenafil exposure and adverse effects.

Concomitant serotonergic antidepressants (SSRIs, SNRIs) and MAO inhibitors increase the risk for serotonin syndrome with dapoxetine.

• Top Interactions To Check: nitrates, alpha‑blockers, CYP3A4 inhibitors, serotonergic antidepressants, and recreational drugs such as amyl nitrites (poppers).

Alcohol, commonly consumed at social gatherings or cottage weekends, can increase dizziness and orthostatic hypotension and may reduce sexual performance, so counsel patients about limiting intake before dosing.

Pharmacists in community practice should actively screen prescription, OTC and recreational drug use; limited remote access in rural areas increases interaction risk.

Cultural Perceptions And Patient Habits (Canadian Context)

Patients wonder whether others in Canada trust imported sexual performance medications.

Canadian attitudes toward sexual health balance pragmatic expectations for safe, evidence‑based care and privacy concerns, leading some patients to be wary of unregulated imports.

Labels in both English and French are often expected, especially in Quebec, where bilingual information and consent are important.

Online forums and communities frequently discuss Super P‑Force, with common themes of convenience, price and scepticism about local availability.

• Patient Habits: buying online, seeking quick fixes and sometimes delaying care due to shame or stigma.

Urban patients often access sexual health clinics or walk‑in services, while rural residents face confidentiality and access barriers that can push them toward online importation.

Clinicians should provide culturally safe counselling and consider language, trust and access barriers for Indigenous and immigrant populations.

Availability And Pricing Patterns (Canada Vs. US & Online)

Cost and availability questions are common when comparing Canadian pharmacies to online suppliers.

Super P‑Force is widely sold via international e‑shops and Indian manufacturers but lacks formal Canadian distribution.

In Canada, sildenafil generics are sold at major chains with DINs and predictable pricing, and some provincial plans subsidise select formulations.

Imported Super P‑Force usually has no DIN, is not covered by ODB, BC PharmaCare or RAMQ, and can be cheaper per tablet online but carries quality uncertainty.

In our online pharmacy, super p force is available without a prescription, with discreet delivery to Canada (English) in 5‑14 days.

• Costs To Consider: shipping fees, customs seizure risk, lack of pharmacist counselling and no provincial reimbursement for non‑DIN imports.

Comparable Medicines And Patient Preferences (Alternatives In Canada)

People commonly ask what to use instead of a combined tablet.

• Pros And Cons Checklist: Sildenafil — established DINs and safety profile; Tadalafil — better for spontaneous activity; Dapoxetine — PRN for PE but limited access; Combination — single‑tablet convenience versus absence of Canadian approval.

Patient preference drivers include efficacy, side effects, cost, privacy and desire for single‑tablet convenience when both ED and PE coexist.

FAQ Section

Q1: Is Super P‑Force approved in Canada?

A1: There is no known Health Canada approval or DIN for the fixed‑dose combination; sildenafil generics are approved as individual products.

Q2: Can I import it for personal use?

A2: Canadians can sometimes import medication for personal use under specific conditions, but this carries risks including customs seizure and lack of quality assurance; consult Health Canada guidance before importing.

Q3: Will provincial drug plans cover it?

A3: Unlikely, because products without a DIN are not eligible for reimbursement under ODB, BC PharmaCare or RAMQ; individual DIN‑bearing agents may be eligible.

Q4: Is it safe to take with my heart medication?

A4: It can be dangerous with nitrates and in unstable cardiac disease; always consult a prescriber or pharmacist before taking sildenafil or any combination tablet.

• When To See A Prescriber: chest pain, recent stroke, syncope, use of nitrates, or any history of priapism.

Guidelines For Proper Use (Pharmacist & Provincial Authority Tips)

Pharmacists and prescribers need clear steps to keep patients safe when dealing with combination requests.

Verify prescription legitimacy and perform a full medication reconciliation that includes OTCs and recreational drugs.

Counsel on dosing limits, emphasise a maximum of one tablet per 24 hours, and screen specifically for nitrates and serotonergic medications.

Document informed consent when supplying off‑label or imported products and advise patients about signs of serotonin syndrome and hypotension.

• Pharmacist Checklist: confirm cardiovascular risk, check hepatic/renal status, explain side effects, advise on alcohol and driving risks, and recommend urgent care for priapism.

For rural pharmacies with limited specialist support, establish telehealth links with sexual health clinics and ensure bilingual counselling where required in provinces such as Quebec.

Storage note: store below 30°C in original blister packaging and keep out of reach of children.

Delivery Across Canada (English)